secwatch.observer — SEC 8-K summary
======================================

Issuer:     DNA X, Inc. (SONM)
CIK:        0001178697
Form:       8-K/A
Filed at:   2026-08-13T20:01:17+00:00
Accession:  0001493152-26-037733
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 3.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

DNA X sells final Series B Preferred for $2.5M; pro forma equity $5.84M exceeds Nasdaq minimum
--------------------------------------------------------------------------------

- On Aug 7, 2026, sold 416,667 Series B Preferred shares for $2.5M cash.
- Pro forma stockholders' equity at Aug 7: $5.84M, above Nasdaq's $2.5M requirement.
- Q1 2026 actual net income $6.34M; Q2 2026 est. net loss $1.53M; Aug 7 est. net loss $639k.
- Adjustments include $4.946M financing, $3.049M note conversion, $963k reclass of redeemable shares.
- Awaiting Nasdaq formal determination of compliance with Listing Rule 5550(b)(1).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178697/000149315226037733/0001493152-26-037733-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178697/000149315226037733/form8ka.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-037733

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer